InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results
InMed Pharmaceuticals Inc. (NASDAQ:INM) will report its financial results for Q3 FY2021 on May 13, 2021. This quarter ended on March 31, 2021. The Company is focused on the development of cannabinoid-based drug candidates, particularly cannabinol (CBN), aimed at addressing high unmet medical needs. A conference call and webcast will occur on the same day at 8:00 AM PT / 11:00 AM ET, with a replay available for 90 days. Full financials will be accessible on InMed's official website as well as SEDAR and SEC platforms.
- None.
- None.
VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol (“CBN”), will report financial results on Thursday, May 13, 2021 for the third quarter of fiscal year 2021 ending March 31, 2021.
Conference Call & Webcast*:
Thursday, May 13, 2021 at 8:00 AM Pacific Time, 11:00 AM Eastern Time
US/CANADA Participant Toll-Free Dial-In Number: +1 (855) 605-1745
US/CANADA Participant International Dial-In Number: +1 (914) 987-7959
Conference ID: 3186833
Webcast: https://edge.media-server.com/mmc/p/ajuejmko
(*Webcast replay available for 90 days)
The Company’s full financial statements and related MD&A for the third quarter ending March 31, 2021 will be available at www.inmedpharma.com, www.sedar.com and at www.sec.gov on May 13, 2021.
About InMed: InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (CBN), in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.
Investor Contact:
Edison Group
Joe Green/Laine Yonker
T: +1.646.653.7030/+1.646.653.7035
E: jgreen@edisongroup.com
lyonker@edisongroup.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines; developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol; leading the way in the clinical development of cannabinol; and reporting financial results on May 13, 2021.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FAQ
When will InMed Pharmaceuticals report its Q3 FY2021 financial results?
What is the focus of InMed Pharmaceuticals' drug development?
What time is the conference call for InMed Pharmaceuticals' financial results?
Where can I access InMed Pharmaceuticals' full financial statements?
